OptiBiotix Health Plc (LON:OPTI) a life sciences company developing a range of products to modify the human microbiome has known for some time the huge market potential that surrounds it’s area of expertise. Jessica Richman knows people are skeptical when she says there’s a trillion-dollar market opportunity around the human microbiome, which is the collection of all the microbes that are in our bodies and on our skin. But that’s exactly what she told angel investors in one of her early pitches for uBiome, her San Francisco-based biotech company that gives consumers information about how their behavior impacts their microbiome.
She says in the video above that further understanding the microbiome will cause a massive change in a number of markets, including lab testing, cosmetics and food.
We asked Stephen OHara, OptiBiotix Health Plc CEO for his thoughts on the video: ‘This interview explores the market opportunities open to microbiome companies as being in the region of trillion dollars. Whilst the exact figure is unknown this interview reflects industry sentiment on the scale of the opportunity. OptiBiotix raised additional funding in November 2015 to leverage its existing technology platforms to extend its reach into other application areas to capitalise on the growing body of scientific evidence supporting the applicability of microbiome modulation in a wider range of health areas. This has led to the acquisition of SkinBiotix IP which we believe is a significant growth opportunity’
